115 S4120 ENR: Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022
U.S. Senate
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
One Hundred Seventeenth Congress of the United States of America
2d Session
Begun and held at the City of Washington on Monday, the third day of January, two thousand and twenty two
S. 4120
IN THE SENATE OF THE UNITED STATES
AN ACT
To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.
1.

Short title
This Act may be cited as the “Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022” or the “Childhood Cancer STAR Reauthorization Act”.
2.

Reauthorizing and improving the Childhood STAR Act
(a)

Children's cancer biorepositories
Section 417E of the Public Health Service Act (42 U.S.C. 285a–11) is amended—
(1)
in subsection (a)—
(A)
in paragraph (2)(A), by inserting before the period at the end of the second sentence the following: “, such as collected samples of both solid tumor cancer and paired samples”;
(B)
in paragraph (9), by striking “Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018” and inserting “Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022”;
(C)
by redesignating paragraph (10) as paragraph (11); and
(D)
by inserting after paragraph (9) the following:
“(10)

Report on researcher access to children's cancer biorepository samples
Not later than 2 years after the date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022, the Director of NIH shall—
(A)
conduct a review of the procedures established under paragraph (2)(C) and other policies or procedures related to researcher access to such biospecimens to identify any opportunities to reduce administrative burden, consistent with paragraph (2)(D), in a manner that protects personal privacy to the extent required by applicable Federal and State privacy law, at a minimum; and
(B)
submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the findings of the review under subparagraph (A) and whether the Director of NIH plans to make any changes to the policies or procedures considered in such review, based on such findings.”; and
(2)
in subsection (d), by striking “2019 through 2023” and inserting “2024 through 2028”.
(b)

Cancer survivorship programs
Section 201 of the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018 (Public Law 115–180) is amended—
(1)
in subsection (a)—
(A)
in the subsection heading, by striking “Pilot programs to explore” and inserting “Research to evaluate”
(B)
in paragraph (1)—
(i)
by striking “may make awards to eligible entities to establish pilot programs” and inserting “shall, as appropriate, make awards to eligible entities to conduct or support research”;
(ii)
by striking “model systems” and inserting “approaches”;
(iii)
by inserting “and adolescent” after “childhood”; and
(iv)
by striking “evaluation of models for”;
(C)
in paragraph (2)—
(i)
in subparagraph (A), in the matter preceding clause (i), by inserting “within the existing peer review process,” after “practicable,”; and
(ii)
in subparagraph (B)(v), by striking “in treating survivors of childhood cancers” and inserting “in carrying out the activities described in paragraph (1)”; and
(D)
in paragraph (3)(B)(v), by striking “design of systems for the effective transfer of treatment information and care summaries from cancer care providers to other health care providers” and inserting “design tools to support the secure electronic transfer of treatment information and care summaries between health care providers or, as applicable and appropriate, longitudinal childhood cancer survivorship cohorts”; and
(2)
in subsection (b)—
(A)
in each of paragraphs (1) and (2), by striking “date of enactment of this Act” and inserting “date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022”; and
(B)
in paragraph (1)—
(i)
by striking subparagraphs (A) and (C);
(ii)
by redesignating subparagraph (B) as subparagraph (A); and
(iii)
by adding at the end the following:
“(B)
recommendations for enhancing or promoting activities of the Department of Health and Human Services related to workforce development for health care providers who provide psychosocial care to pediatric cancer patients and survivors.”.
Speaker of the House of Representatives
Vice President of the United States and President of the Senate